自身免疫及炎症性疾病免疫抑制患者的皮肤鳞状细胞癌累积率
这项回顾性队列研究纳入94例免疫抑制的自身免疫/炎症性疾病患者和188例免疫正常对照,评估2010至2020年原发性侵袭性皮肤鳞状细胞癌(CSCC)的累积率。结果显示免疫抑制患者CSCC累积率显著高于对照(0.82±0.95 vs 0.44±0.36,P<.01),且与免疫调节剂、TNF-α抑制剂、非TNF-α抑制剂生物制剂及糖皮质激素暴露相关。
要点
- 自身免疫/炎症性疾病免疫抑制患者CSCC年累积率显著高于免疫正常者。
- 各疾病亚型(RA、IBD、银屑病等)CSCC累积率均显著升高。
- 系统用药暴露与CSCC累积率增加相关,但用药类别数及免疫抑制时长无关。
核心结论
- 自身免疫及炎症性疾病患者CSCC累积率高于免疫正常患者。
研究设计与样本
- 回顾性队列研究,纳入94例免疫抑制患者(类风湿关节炎31例[33.0%]、炎症性肠病17例[18.1%]、银屑病11例[11.7%]、其他自身免疫病24例[25.5%]、其他炎症性疾病21例[22.3%])和188例免疫正常对照,识别2010至2020年诊断的原发性侵袭性CSCC。
主要发现
- 免疫抑制患者总CSCC累积率为0.82±0.95,高于免疫正常对照的0.44±0.36(P<.01)。
- 类风湿关节炎患者累积率为0.88±1.10(P<.01),炎症性肠病为0.94±0.88(P<.01),银屑病为1.06±1.58(P<.01),其他自身免疫病为0.72±0.56(P<.01),其他炎症性疾病为0.72±0.61(P<.01)。
- CSCC累积率增加与免疫调节剂、TNF-α抑制剂、非TNF-α抑制剂生物制剂及糖皮质激素暴露相关。
- CSCC累积率与系统用药类别数量或免疫抑制持续时间无关。
临床怎么用
- 对自身免疫及炎症性疾病使用免疫抑制治疗的患者应关注CSCC筛查。
局限性
- 回顾性、单中心研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunosuppression is a known risk factor for the development of cutaneous squamous cell carcinoma (CSCC), especially in solid organ transplant recipients and chronic lymphocytic leukemia. However, this risk is less well defined in autoimmune and inflammatory conditions. OBJECTIVE: Assess the impact that disease-type, duration of immunosuppression, and systemic medications have on CSCC accrual rates, defined as the number of CSCCs a patient develops per year, in autoimmune and inflammatory conditions. METHODS: Retrospective review of 94 immunosuppressed (rheumatoid arthritis: 31[33.0%], inflammatory bowel disease: 17[18.1%], psoriasis: 11[11.7%], autoimmune other (AO): 24[25.5%], inflammatory other: 21[22.3%]) and 188 immunocompetent controls to identify all primary, invasive CSCCs diagnosed from 2010 to 2020. RESULTS: Immunosuppressed patients had higher CSCC accrual rates than immunocompetent controls (0.44 ± 0.36): total cohort (0.82 ± 0.95, P < .01), rheumatoid arthritis (0.88 ± 1.10, P < .01), inflammatory bowel disease (0.94 ± 0.88, P < .01), psoriasis (1.06 ± 1.58, P < .01), AO (0.72 ± 0.56, P < .01), and inflammatory other (0.72 ± 0.61, P < .01). There was an association between increased tumor accrual rates and exposure to systemic medications including, immunomodulators, tumor necrosis factor-alpha inhibitors, non-tumor necrosis factor inhibitor biologics, and corticosteroids, but not with number of systemic medication class exposures or duration of immunosuppression. LIMITATIONS: Retrospective, singlecenter study. CONCLUSION: Patients with autoimmune and inflammatory conditions accrue CSCCs at higher rates than immunocompetent patients.
引用
- Granger EE, Groover M, Harwood C, et al. Cutaneous squamous cell carcinoma tumor accrual rates in immunosuppressed patients with autoimmune and inflammatory conditions: A retrospective cohort study. J Am Acad Dermatol. 2023. PMID: 38043592. doi:10.1016/j.jaad.2023.11.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。